DLA Piper has advised Croda International Plc on the acquisition of Danish pharmaceutical company

Croda has signed a deal with Brenntag Nordic A/S to acquire 100% of the share capital in Brenntag Biosector A/S for EUR 72 million in cash. 

Brenntag Biosector A/S, which is headquartered in Ballerup, Denmark, is a specialist in the manufacture and supply of adjuvants for vaccines. Its product portfolio includes innovative aluminium and saponin-based adjuvants used in both human and veterinary vaccines to enhance their efficacy.

Brenntag Biosector A/S, upon completion of the deal, will be integrated into Croda’s existing health care business in the life sciences sector and will continue to be led by its current management team.

DLA Piper has advised Croda International Plc throughout the transaction process, which is expected to be completed by the end of December 2018.

The DLA Piper team consisted of Ulrik Bangsbo Hansen, Andreas Brasch-Thomsen, Glenn Schmidt-Hansen, Daniel Markussen and Kristine Hansen, with assistance from DLA Piper’s other specialists.